Crossmark

Cannabis-based magistral formulation is highly effective as an adjuvant treatment in drug-resistant focal epilepsy in adult patients: an open-label prospective cohort study

Crossref DOI link: https://doi.org/10.1007/s10072-022-06393-1

Published Online: 2022-09-21

Published Print: 2023-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Navarro, Cristian Eduardo https://orcid.org/0000-0003-0532-6301
License Information

Text and Data Mining valid from 2022-09-21

Version of Record valid from 2022-09-21
More Information

Article History

Received: 18 August 2022

Accepted: 8 September 2022

First Online: 21 September 2022

Declarations

:

: The institutional review board approved the study.

: Patients provided written informed consent to participate and to use a cannabis-based magistral formulation (CBMF).

: Cristian Eduardo Navarro MD MSc works at Clínica Zerenia in Bogotá (Colombia) which is a reference center specializing in medical cannabis therapy owned by Khiron Life Science Corp®. Khiron Life Science Corp.® manufactures the cannabis-based magistral formulation used in this study.

: Informed consent was provided by each patient at the beginning of the study.

Document is current

Any future updates will be listed below